Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

157
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
157
Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

484
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
484
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

287
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
287
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

226
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
226
Survival Curves01:18

Survival Curves

205
Survival curves are graphical representations that depict the survival experience of a population over time, offering an intuitive way to track the proportion of individuals who remain event-free at each time point. These curves are widely used in fields such as medicine, public health, and reliability engineering to visualize and compare survival probabilities across different groups or conditions.
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
205
Cancer Survival Analysis01:21

Cancer Survival Analysis

394
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
394

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

A Simulation and Case Study to Evaluate the Extrapolation Performance of Flexible Bayesian Survival Models when Incorporating Real-World Data.

Medical decision making : an international journal of the Society for Medical Decision Making·2026
Same author

Can we develop prognostic models for estimating life expectancy following a cancer diagnosis? Evaluating model complexity, data requirements, and optimal modelling frameworks.

Cancer epidemiology·2026
Same author

Evaluating the Impact of Different Natural History Modeling Methods on Cost-Effectiveness Decisions: A Case Study in Duchenne Muscular Dystrophy.

MDM policy & practice·2026
Same author

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same author

Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry.

Internal medicine journal·2026
Same author

International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study.

The Lancet. Oncology·2026

Related Experiment Video

Updated: Jul 23, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K

Survival Extrapolation Incorporating General Population Mortality Using Excess Hazard and Cure Models: A Tutorial.

Michael J Sweeting1, Mark J Rutherford2, Dan Jackson1

  • 1Statistical Innovation, AstraZeneca, Cambridge, UK.

Medical Decision Making : an International Journal of the Society for Medical Decision Making
|July 14, 2023
PubMed
Summary

Excess hazard (EH) methods incorporating general population mortality data can reduce uncertainty in long-term survival extrapolations for cost-effectiveness analyses. EH cure models are particularly effective when cure is plausible, significantly decreasing variability in survival estimates.

Keywords:
excess hazard modelshealth technology assessmentmodelingoverall survivalsurvival extrapolation

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

306

Related Experiment Videos

Last Updated: Jul 23, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.2K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

306

Area of Science:

  • Health economic modeling
  • Biostatistics
  • Survival analysis

Background:

  • Parametric survival models in cost-effectiveness analyses can yield discordant extrapolations and decision uncertainty.
  • Excess hazard (EH) methods offer a potential solution by incorporating general population mortality data to reduce model uncertainty.
  • This review focuses on practical considerations for using EH methods in long-term survival estimation.

Approach:

  • A case study involving 686 patients with low and high-grade breast cancer was analyzed.
  • Seven standard parametric survival models were compared with EH models, both with and without a cure parameter.
  • Survival extrapolations, restricted mean survival time (RMST), and cure fraction estimates were compared, alongside sensitivity analyses for lifetable misspecification.

Key Points:

  • Standard models showed extensive variability in 30-year RMST (7.5 to 14.3 years).
  • EH cure methods significantly reduced model uncertainty compared to standard models and EH models without cure.
  • Long-term treatment effects approached the null across most models at varying rates, with minimal impact of lifetable misspecification on RMST differences.

Conclusions:

  • EH methods are valuable for survival extrapolation, especially in cancer where excess hazards may decrease over time.
  • EH cure models are beneficial when cure is plausible, leading to reduced extrapolation variability.
  • EH methods demonstrate robustness to lifetable misspecification.